The European healthcare technology sector has entered a protracted period of structural realignment, precipitated by the breakdown of the historical venture capital funding escalator. Between 2020 and 2021, zero-interest-rate monetary policies and temporary pandemic tailwinds channeled speculative capital into early-stage digital health platforms, creating inflated entry valuations and subsidising unsustainable operational burn rates.